Loading organizations...
Biotechnology company engineering stabilized enzymes and therapeutics using computational tools for biotech and industrial partners.
Aperiam Bio is an Austin, Texas-based biotechnology company that develops advanced computer vision algorithms and machine learning technology to engineer highly stabilized, solubilized, and catalytically optimized proteins. The enterprise operates through a collaborative business-to-business partnership model, working directly with industrial enzyme manufacturers and pharmaceutical organizations to identify critical protein chemistry and deliver mutated variants for internal partner validation. Operating with a dedicated team of one to ten employees, the firm officially emerged from stealth operations in December 2023 after successfully securing $9 million in initial seed funding. This financing round was led by OMX Ventures to support the continued development of proprietary computational tools alongside executives including Head of Program Guillaume Cottarel and Chief Business Officer Russell Durrett. The biotechnology company was founded in 2021 by evolutionary biologist and protein engineer Austin Cole.
Aperiam Bio has raised $9.0M across 1 funding round.
Aperiam Bio has raised $9.0M in total across 1 funding round.
Aperiam Bio has raised $9.0M in total across 1 funding round.
Aperiam Bio's investors include Nick Haft, Axial VC, Civilization Ventures, KdT Ventures.
Aperiam Bio has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Seed in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 29, 2023 | $9.0M Seed | Nick Haft | Axial VC, Civilization Ventures, KdT Ventures |